Consensus

Brazilian Protocol for Sexually Transmitted Infections 2020: viral hepatitis

Geraldo Duarte[1], Paula Pezzuto[2], Tiago Dahrug Barros[2], Gláucio Mosimann Junior[2] and Flor Ernestina Martinez-Espinosa[3]

[1]. Universidade de São Paulo, Faculdade de Medicina de Ribeirão Preto, Ribeirão Preto, SP, Brasil.
[2]. Ministério da Saúde, Secretaria de Vigilância em Saúde, Brasília, DF, Brasil.
[3]. Fundação Oswaldo Cruz, Instituto Leônidas e Maria Deane, Manaus, AM, Brasil.

Abstract

This article discusses viral hepatitis, a theme addressed by the Clinical Protocol and Therapeutic Guidelines to Comprehensive Care for People with Sexually Transmitted Infections and, more precisely, by the Clinical Protocols and Therapeutic Guidelines for Hepatitis B and Hepatitis C and Coinfections, published by the Brazilian Ministry of Health. Besides the broad spectrum of health impairment, hepatitis A, B, and C viruses also present different transmission forms, whether parenteral, sexual, vertical, or fecal-oral. Among the strategies suggested for the control of viral hepatitis, in addition to behavioral measures, are expanded diagnosis, early vaccination against hepatitis A and hepatitis B viruses, and access to available therapeutic resources. Considering vertical transmission of the hepatitis B and hepatitis C viruses, screening for pregnant women with chronic hepatitis B and C is an essential perinatal health strategy, indicating with precision those who can benefit from the prophylactic interventions.

Keywords: Hepatitis A. Hepatitis B. Hepatitis C. Vaccines. Therapeutics. Disease prevention.

Highlighted excerpt: Viral hepatitis A, B, and C are responsible for more than 1.34 million deaths worldwide every year, from which 66% are the result of hepatitis B, 30% of hepatitis C, and 4% of hepatitis A.

EPIDEMIOLOGICAL ASPECTS

Viral hepatitis A, B, and C are caused by viruses presenting primary hepatic tissue tropism, posing a significant challenge to public health worldwide. Such infections are responsible for more than 1.34 million deaths worldwide every year, from which 66% are the result of hepatitis B, 30% of hepatitis C, and 4% of hepatitis A. These deaths mainly arise from complications of hepatitis chronic forms, such as hepatic failure, cirrhosis, and hepatocellular carcinoma. Such significant data made the World Health Organization (WHO) assume, as one of its goals, ending viral hepatitis until 2030.

From 1999 to 2019, the Notifiable Disease Information System registered 673,389 viral hepatitis cases in Brazil. From such amount, 168,036 (25%) were hepatitis A, 27,890 (36.8%), hepatitis V, 253,307 (37.6%), hepatitis C, and 4,156 (0.6%), hepatitis D.

Hepatitis A virus (HAV) belongs to the Picornaviridae family, and its genome consists of ribonucleic acid (RNA), commonly transmitted through the fecal-oral route, contaminated food, and water ingestion. Its sexual transmission has been specially reported in men who have sex with men, which reinforces the need for including prevention measures among adults.
Hepatitis B virus (HBV) belongs to the *Hepadnaviridae* family, whose genetic variations lead to ten different genotypes. The genotypes have relevant epidemiologic, clinical, and therapeutic aspects\(^{1,3,4}\). Among the viruses considered hepatotropic, it is the only one with genome material composed of deoxyribonucleic acid (DNA). The most frequent HBV transmission modes are parenteral or percutaneous exposure, either vertical or sexual\(^{1}\). Blood is the most important transmission vehicle, but other fluids can transmit HBV as well, such as semen and vaginal content\(^{1}\). Predominant transmission routes vary according to HBV infection prevalence. In areas with high prevalence, perinatal and children's close contact routes are the virus's primary transmission forms\(^{16,17}\). In low-prevalence areas, percutaneous route and sexual contact are the contamination forms posing the greatest risk\(^{18}\).

Hepatitis C virus (HCV) belongs to the *Flaviridae* family, whose genetic material is composed of a positive-sense single strand RNA, and its genetic variation allows recognizing seven different genotypes\(^{19}\). Its transmission takes place through percutaneous, sexual, and vertical exposure. The occurrence frequency for each of such categories varies according to the studied population and associated factors comitance. However, it should be highlighted that the parenteral route is more efficient and prevalent in HCV transmission than sexual and vertical transmission. The highest number of new infections has been observed among injectable drug users and through syringe and needle sharing\(^{20,21}\).

It is known that HCV sexual transmission is more frequent among men who have sex with men\(^{22}\). As for other sexually transmitted infections, the presence of other STI, ulcerative or not, for example, human immunodeficiency virus (HIV), and unprotected sexual practices, especially those posing the greater risk of mucous bleeding (anal sex without lubricant, upper limb introduction in the vagina or anus, group sex, sexual object sharing, and sex under psychoactive drug effects), are a significant group of situations and factors facilitating HCV transmission\(^{23,24}\). Although HCV transmission is lower in people with heterosexual habits, and it is higher among those with a large number of sex partners or who perform anal sex\(^{23}\).

**CLINICAL ASPECTS**

Hepatitis A is self-limited, it does not evolve to a chronic disease, and its main control form is the vaccine\(^{25}\). Its incubation period varies from 15 to 50 days, and it is symptomatic in 70% of adults\(^{16,27}\). It is characterized by a sudden start of nausea, vomit, anorexia, fever, discomfort, and abdominal pain, followed by jaundice, choloria, acholia, and pruritus\(^{28}\). People with HAV infection transmit the virus during the incubation period, which lasts from one to six months, persisting up to one week after jaundice starting\(^{29}\).

HBV hepatitis can be a chronic or acute disease. In the acute form, around 70% of the cases present the subclinical form, and 30% the jaundice form, which is linked to a possibly more severe disease course\(^{26,31}\). In the acute phase, clinical manifestations, such as anorexia, weakness, discomfort, nausea, jaundice, choloria, and abdomen right upper quadrant pain cannot be distinguished from other viral hepatitis\(^{32}\). In HBV hepatitis, the progression rate of acute to chronic infection in immunocompetent individuals is determined mainly by the age when the infection takes place, being 90% in vertical transmission\(^{31}\), 20% to 50% from one to five years old\(^{43,35}\), and 0% to 10% after adolescence\(^{12,36}\). In its chronic form, hepatitis B is frequently asymptomatic, but it can evolve to chronic hepatic failure, cirrhosis, and hepatocellular carcinoma\(^{37}\).

HCV infection has a high chronification rate, and around 50% to 85% of people evolve to the chronic infection form. Symptoms are present in a minority of cases (20 to 30%), and are mainly unspecific manifestations such as tiredness, changes in sleeping, nausea, diarrhea, abdominal pain, anorexia, myalgia, arthralgia, weakness, behavior changes, and weight loss\(^{28,39}\). Extrahepatic manifestations include cryoglobulinemia, membranoproliferative glomerulonephritis, autoimmune thyroiditis, porphyria cutanea tarda, among others\(^{46}\). In case of lack of spontaneous viral elimination or treatment, an average of 20% of HCV infection cases evolve to cirrhosis over time\(^{41}\).

**DIAGNOSIS**

Hepatitis A, B, and C diagnosis is based on detecting serological (specific viral antigens and antibodies) and molecular (viral nucleic acid) markers in the infected person's blood, serum, plasma, or oral fluid, through immunoassays or molecular biology techniques\(^{12,42,43}\). Rapid test incorporation to the Brazilian National Health System (SUS) expended testing and early detection opportunities of such infections. They can be conducted in places without laboratory infrastructure or hard to access\(^{44}\).

For acute hepatitis A diagnosis, immunoassay tests detecting anti-HAV IgM antibodies in serum (up to six months after symptom starting) are used. IgG anti-HAV antibodies search, either through anti-HAV IgG or total anti-HAV (IgM and IgG), helps identify non-immunized or previously infected individuals. Such examinations must be requested for people exposed to this infection risk situation\(^{44,45}\). Anti-HAV IgG antibodies presence indicates long-lasting immunity\(^{16}\).

Most of the people with HBV infections are asymptomatic and diagnosed in the chronic disease phase. Figure 1 shows the variation time dynamics of infection markers\(^{37}\). The succinct definition of such markers is given in Figure 2\(^{46}\). For infection screening, an immunoassay laboratory test or a rapid test is used for detecting the HBV surface antigen (HBsAg). If positive, the diagnosis is supplemented by total anti-HBc, and, if possible, molecular test (HBV-DNA). HBeAg, anti-HBe, and anti-HBs, alongside the other markers, help in the clinical phase assessment and the infection evolution monitoring\(^{16,37,42,44,49}\).

In acute hepatitis B, HBsAg, HBeAg, anti-HBc IgM, and HBV-DNA are the first markers to be detected. HBsAg presence confirms the infection, and it can be detected from two to 12 weeks after exposure to the virus. Its disappearance indicates that the infection has been resolved and takes place weeks after the detection, lasting for up to six months. Anti-HBc IgM disappears after the acute infection control but can be detected during flares of chronic hepatitis B\(^{48}\).
HBeAg marks intense viral replication, and its detection is associated with high HBV infectiousness\textsuperscript{48}. Anti-HBc IgG antibodies also have an early appearance, and they usually persist for life. They cannot classify clinical form because all infected individuals, either cured or not, present this marker. It has an epidemiological use because it indicates the previous contact with the virus or current infection. Anti-HBe presence indicates recovery starting, but many individuals presenting the disease chronic replicative form can have this marker in case of HBeAg absence\textsuperscript{50}. Anti-HBs marker arises during the convalescent phase, after HBsAg disappearing. Its presence indicates immunity against HBV. In case of lack of anti-HB, the total anti-HBc is the only isolated marker of the previous infection. In individuals not exposed to HBV (negative anti-HBc IgG), anti-HBs antibodies presence indicate immunity through vaccine response for hepatitis B\textsuperscript{51}.
If patients do not achieve acute infection resolution, some individuals become HBV chronic carriers. In such cases, HBsAg persistence for more than six months indicates chronic infection. In chronic hepatitis B, HBsAg and HBV-DNA markers stay present and detectable. The HBeAg and anti-HBe assessment, together with HBV-DNA and ALT, help monitor and assess the clinical infection phase.

Hepatitis B testing can be offered or requested for every person with high vulnerability to the disease. Those whose results are negative must be vaccinated. In HCV infection, most infected people are asymptomatic, and tracking is conducted through anti-HCV antibody detection using immunoassay tests or rapid tests. In people with reactive results, the diagnosis is supplemented by a molecular test, in this case, the reverse transcriptase-polymerase chain reaction (RT-PCR) for detecting HCV's RNA, confirming active, acute, or chronic infection. Hepatitis C testing must be requested for all individuals in risk situations regarding this infection.

**TREATMENT**

A hepatitis A-specific antiviral treatment is not available. There are only medications for relieving symptoms, which generally disappear in two months.

Only support measures are enough during HBV acute infection, considering more than 90% present spontaneous resolution. In case of need for treatment, reverse transcriptase inhibitors are used. In Brazil, the choice is tenofovir disoproxil fumarate or entecavir. Preventive measures must be taken for all exposed contacts, indicating immunoglobulin and vaccination for serum-negative cases or those presenting unknown serology, according to the set criteria.

After six months of HBsAg persistence in blood, HBV infection is considered chronic, and it must be clinically and virologically assessed for a decision on the need for drug therapy. Hepatitis B chronic form treatment aims mainly at viral suppression, thus avoiding the hepatopathy's evolution and death. HBsAg disappearance and seroconversion for antiHBs (functional cure) would be the ideal result, but it is rarely achieved. When such an objective is not attained, anti-HBe emergence, viral load reduction, and hepatic enzyme normalization are alternative outcomes.

Due to its complexity, this treatment must be set under specialist guidance because it depends on multiple clinical and laboratory variables, such as the presence of significant hepatic disease, immune response to infection, viral load, and risk factors for disease progression (age and hepatocellular carcinoma family history). Liver biopsy can help assess the tissue aggression degree and cases in need of dismissing base liver disease. The definition of HBV chronic infection antiviral therapy depends, at first, on the hepatopathy degree, on the concentration of aminotransferases, and viral load (HBV-DNA).

HCV infection can be objectively cured by using direct-action antiviral treatment. However, as it is an asymptomatic infection in most cases, a significant number of infected people are not diagnosed, many patients remain without therapy. This treatment must be followed by a specialist, considering its complexity.

Therapeutic alternatives for HCV infection treatment incorporated into SUS show high therapeutic effectiveness, confirmed by a sustained virological response. When comparing similar clinical situations, all proposed schemes present analogous effectiveness. Characteristics differentiating them are recommendations for certain populations, ease posology, more affordable control, and cost. The therapy aims to sustain virological response, which means viral RNA's continuous disappearance after 12 to 24 weeks after treatment.

**SURVEILLANCE, PREVENTION, AND CONTROL**

Viral hepatitis case notification is compulsory for all Brazilian states since 2016. All suspected cases must also be reported weekly to the health authority.

According to the Special Immunobiological Reference Center's criteria, HAV infection prevention depends on the improvement of the population's sanitary conditions and vaccination (children up to five years old and people exposed to greater risk of infection). However, in adults, the sexual transmission must also be taken into account, indicating and encouraging safe sex practices. In case of hepatitis A risk exposure, the testing is recommended, and negative people can be vaccinated up to 14 days after exposure.

---

### Main medications and most frequent associations for hepatitis C treatment

| Medications                                      |
|--------------------------------------------------|
| Sofosbuvir + daclatasvir                          |
| Sofosbuvir/ledipasvir                             |
| Sofosbuvir/velpatasvir                            |
| Elbasvir/grazoprevir                              |
| Glecaprevir/pibrentasvir                          |
| Ribavirin                                         |

*Source: adapted from the Clinical Protocol and Treatment Guidelines for Hepatitis C and Coinfections.*

**FIGURE 3:** Main medications and most frequent associations for hepatitis C treatment.
For HBV infection control, the best strategy is vaccination, which presents high effectiveness percentages varying according to age (preterm children and people older than 60 years show lower proportions of serological conversion) and the presence of comorbidities, such as hemodialysis, hepatopathies, cancers, and people with HIV. Ninety percent of HBV infections acquired in the perinatal period evolving to the chronic form gives room for universal vaccination strategies of all newborns, regardless of the mother’s chronic virus carrier status. This strategy is crucial for achieving the goal of controlling hepatitis B up to 2030.

Recommendations and care with people using illicit drugs and those performing adequate unprotected sex activity are strategies that can bring better results in HCV infection reduction. Another way of controlling HCV infections is the direct-action antiviral therapy, whose success extended the discussion on treatment as a disease prevention strategy.

**SPECIAL POPULATIONS AND SITUATIONS**

The approach to HAV, HBV, and HCV hepatitis during pregnancy requires attention to the prophylactic aspects encompassed both in this virus horizontal and vertical transmission. For risk exposure reduction and control, primary prophylaxis sanitary and behavioral principles are needed, together with active and passive immunoprophylaxis, when available. It is known that HBV and HCV vertical transmission control depends on the universal screening of such infections during prenatal care. In general, during prenatal care, it is important to identify if non-infected pregnant women's partners carry such infections, allowing them to reduce acute infections during pregnancy, for example, including the partner in prenatal care services.

**Hepatitis A during pregnancy**

The short viremia period and care during delivery (avoiding the fetus' contact with the mother's stool) justify HAV vertical transmission's rare character. Vaginal delivery is the recommendation for such women, and natural breastfeeding is authorized.

Both immunoglobulin and the HAV vaccine are safe for being used during pregnancy. In case of exposure to clinical, occupational, and lifestyle risk factors, in addition to travels to areas with high prevalence, immunoprophylaxis can be used.

**Hepatitis B during pregnancy**

The earlier the infection takes place, the higher HBV infection chronicity rates are. For this reason, controlling vertical transmission can reduce chronic hepatitis, cirrhosis, and hepatocellular carcinoma. HBsAg search is recommended as soon as possible in prenatal care, and its repetition is recommended at the moment of delivery. For seronegative pregnant women, the three-dose vaccine scheme must start. The vaccine information does not exclude the need for checking if the pregnant women carry HBV in all such moments because vaccine serological conversion is not assured even after three doses of the vaccine.

With normal liver function, the HBV infection prognostic is not changed by pregnancy, and the infection does not modify the pregnancy prognosis. In case of compromised liver, maternal and perinatal prognoses can be negatively affected.

HBV vertical transmission occurrence is influenced by the viral load, the carrier's HBeAg and anti-HBe positivity, and gestational age (infection acquired by its end increases the risk for high viral load at the moment of delivery). Without prophylactic intervention, the vertical transmission risk in chronic carriers varies from 5% to 30% (8% mean). However, if the pregnant woman carries HBeAg, the vertical transmission rate is high but extremely variable, taking place from 80% to 90% of cases.

During the prenatal care of HBV chronic carriers, all invasive conducts on the fetus and amniotic sac (amniocentesis and cordocentesis) are contraindications. When there is risk exposure, immunoprophylaxis is recommended, using, in different muscle groups, the first vaccine dose and hyperimmune hepatitis B immunoglobulin (0.06mL/kg of body weight, maximum 5mL, intramuscular). In addition to the usual laboratory routine, the following examinations must be requested for pregnant women carrying HBV: liver function test, infection markers still not requested (HBeAg, anti-HBc, anti-HBe, anti-HBs), and viral load. All pregnant women presenting HBV viral load higher than 200,000IU/mL (corresponding to one million copies/mL) or HBeAg positivity must undergo vertical transmission prophylaxis. Changes in liver function indicate the need for long-term treatment and not only prophylaxis (Figure 4).

For HBV vertical transmission prophylaxis, using inhibitors of the nucleoside reverse transcriptase (lamivudine, tenofovir, and telbivudine) is recommended. In Brazil, the option is tenofovir disoproxil fumarate (300mg, per os, single daily dose), started from the 28th week of pregnancy, lasting to postpartum period to prevent the possible increase of viral load. Considering the need for long-term treatment in pregnant women carrying HBV, tenofovir disoproxil fumarate is also used. Entecavir using during pregnancy is not considered safe, and it must be avoided in such a period. Likewise, its use is not recommended while breastfeeding.

Vaginal delivery is authorized to women carrying HBV, preventing episiotomy and deliveries using instruments (forceps or vacuum) and rapidly clamping the umbilical cord. Natural breastfeeding is also allowed.

All newborns from women with HBV must take the vaccine first dose and HBV-specific immunoglobulin (0.5mL intramuscular), preferably in the first 12 hours of their lives, as presented in the algorithm Figure 4. After this first dose, there are many schemes for administering additional vaccine doses, some with two, others with three doses. Countries like China, Malaysia, and Hong Kong, among others, use the schedule with two additional doses administered in the second and sixth months of life of the newborn. In the United States and Canada, the schedule with two additional doses administered in the second and sixth months of life is also used. However, in preterm newborns or cases of...
Universal screening with serological test (HBsAg)\textsuperscript{a}

- Positive HBsAg
- Negative HBsAg

HBV\textsuperscript{b} viral load or HBeAg\textsuperscript{c} (if load is not available, assess liver function)

- Viral load (< 200,000 UI/mL) or negative HBeAg
- Viral load (≥ 200,000 UI/mL) or positive HBeAg
- Viral load (> 200,000 UI/mL) Persistent aminotransferase changes > twice normal value

Without medication prophylaxis
Start prophylaxis with tenofovir
Start long-term therapy\textsuperscript{d}

First HBV vaccine dose and specific immunoglobulin in the newborn
Schedule the next vaccine doses

Source: altered and adapted from World Health Organization, 2020\textsuperscript{71}.

Notes: a) HBsAg – HBV surface antigen; b) HBV: Hepatitis B virus; c) HBeAg – HBV antigen “e”; d) Start long-term therapy with tenofovir disoproxil fumarate because entecavir is not safe for breastfeeding women\textsuperscript{80,81}.

FIGURE 4: Algorithm of preventive interventions for hepatitis B virus vertical transmission prevention.

---

weight lower than 2.0kg, the vaccine scheme considers three additional doses administered in the second, fourth, and sixth months of life\textsuperscript{75,86}. In Brazil, the National Immunization Program recommends the vaccine scheme with three additional doses to the one administered at the moment of birth, using combined vaccines (pentavalent vaccine) administered in the second, fourth, and sixth months of life, regardless of newborn's prematurity or weight\textsuperscript{74,87}.

Whether the vaccine scheme is used, the newborn's situation must be followed-up until infection confirmation or disregarding and assessed serum conversion\textsuperscript{71}. In Brazil, such assessment is recommended from 30 and 60 days after the last dose of anti-HBV vaccine\textsuperscript{74}.

Hepatitis C during pregnancy

In 2020, the Ministry of Health added the universal screening of HCV infection during pregnancy\textsuperscript{88}. As there is no pharmacological prophylaxis for reducing HCV vertical transmission, there is resistance to screening the virus during prenatal care\textsuperscript{4}. However, behavioral and assistance strategies minimize such risk, such as prophylactically and therapeutically controlling other infections, excluding invasive perinatal procedures on the amniotic sac and the fetus, and preventing long-term chorioamnionitis. During delivery, the use of episiotomy must be avoided. The rapid clamping of the umbilical cord is recommended\textsuperscript{65,89,90}. Also, it is one more opportunity for identifying HCV carriers who can benefit from the treatment later.

HCV vertical transmission occurs from 3.8% to 7.8% of pregnant women with chronic infection, showing a positive relationship with the viral load\textsuperscript{89,91-93}. Such vertical transmission rates also vary depending on the gestational age when the acute infection occurs and on the presence of comorbidities, such as HIV infection\textsuperscript{94,95}. There is no confirmation that HCV can cause fetal malformation\textsuperscript{96}.

HCV infection in pregnant women is associated with adverse perinatal prognostics, such as fetal growth restriction and prematurity\textsuperscript{97,98}. Such results do not seem to arise only from HCV effects but from the different factors coexisting in pregnant women\textsuperscript{94}. Regardless of the action taken alone or in association, the need to identify pregnant women with this infection and provide appropriate prenatal care and follow-up for their children is underlined\textsuperscript{88,99}. Both vaginal delivery and natural breastfeeding are authorized for women with HCV\textsuperscript{76,79} provided that there is no concomitance with HIV infection\textsuperscript{100}.

ACKNOWLEDGMENTS

The authors acknowledge this work's contribution by the technical group of specialists responsible for developing the CPTG for Comprehensive Care for People with STI in 2020 and the CPTG for Hepatitis B and Coinfections and CPTG for Hepatitis C and Coinfections, published by the Ministry of Health.

AUTHORS’ CONTRIBUTIONS

Duarte G, Pezzuto P, Barros TD, Mosimann Junior G, and Martinez-Espinosa FE contributed with the concept, design,
drafting, and critical review of the manuscript. All the authors approved the final version of the work and are responsible for all its aspects, including the assurance of accuracy and integrity.

ORCID
Geraldo Duarte - 0000-0002-1689-6142
Paula Pezzuto - 0000-0001-9570-8244
Tiago Dahrug Barros - 0000-0001-6960-3801
Gláucio Mosimann Junior - 0000-0002-1687-5026
Flor Ernestina Martinez-Espinosa - 0000-0002-0325-3674

REFERENCES
1. Brasil. Ministério da Saúde. Portaria MS/SCTIE nº 42, de 5 de outubro de 2018. Torna pública a decisão de aprovar o Protocolo Clínico e Diretrizes Terapêuticas para Atenção Integral às Pessoas com Infeccões Sexuamente Transmissíveis (IST), no âmbito do Sistema Único de Saúde – SUS [Internet]. Diário Oficial da União, Brasília (DF), 2018 out 8 [cited 2018 Oct 15];Seção 1:88. Available from: http://conitec.gov.br/images/Relatorios/Portaria/2018/Portaria_SCTIE_N42_05_10_2018.pdf
2. Brasil. Ministério da Saúde. Portaria nº 43, de 9 de dezembro de 2016. Torna pública a decisão de atualizar o Protocolo Clínico e Diretrizes Terapêuticas para Hepatite B e coinfeccões, no âmbito do Sistema Único de Saúde – SUS [Internet]. Diário Oficial da União, Brasília (DF), 2016 Dec 9 [cited 2019 Dec 16];Seção 1:121. Available from: http://conitec.gov.br/images/Relatorios/Portaria/2016/Portaria_SCTIE_47_2016.pdf
3. Brasil. Ministério da Saúde. Portaria MS/SCTIE nº 84, de 19 de dezembro de 2018. Torna pública a decisão de aprovar o Protocolo Clínico e Diretrizes Terapêuticas para Hepatite C e coinfeccões, no âmbito do Sistema Único de Saúde – SUS [Internet]. Diário Oficial da União, Brasília (DF), 2018 Dec 20 [cited 2018 Oct 15];Seção 1:187. Available from: http://conitec.gov.br/images/Relatorios/Portaria/2018/PortariasSCTIE_82a4_2018.pdf
4. World Health Organization - WHO. Global hepatitis report, 2017 [Internet]. Geneva: World Health Organization; 2017 [cited 2020 Oct 15]. Available from: https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/
5. Thomas DL. Global elimination of chronic hepatitis. N Engl J Med [Internet]. 2019 May [cited 2020 Oct 15];380(21):2041-50. https://doi.org/10.1056/NEJMma1810477
6. World Health Organization - WHO. Global health sector strategy on viral hepatitis 2016-2021: towards ending viral hepatitis [Internet]. Geneva: World Health Organization; 2016 [cited 2020 Oct 15]. Available from: https://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-eng.pdf;jsessionid=65FC34B07F74743FC634F238D44E5E77?sequence=1
7. Ministério da Saúde (BR). Secretaria de Vigilância em Saúde. Departamento de Doenças de Condições Crônicas e Infeccões Sexualmente Transmissíveis. Hepatites virais | 2020. Bol Epidemiol [Internet]. 2020 Jul [cited 2020 Oct 15];especial. Available from: http://www.aids.gov.br/pt-br/pub2020/boletim-epidemiologico-hepatites-virais-2020
8. Cotter SM, Sansom S, Long T, Koch E, Kellerman S, Smith F, et al. Outbreak of hepatitis A among men who have sex with men: implications for hepatitis A vaccination strategies. J Infect Dis [Internet]. 2003 Apr [cited 2020 Oct 15];187(8):1235-40. Available from: https://doi.org/10.1086/374057
9. Beebejaun K, Degala S, Balogun K, Simms I, Woodhall SC, Heinsbroek E, et al. Outbreak of hepatitis A associated with men who have sex with men (MSM), England, July 2016 to January 2017. Euro Surveill [Internet]. 2017 Feb [cited 2020 Oct 15];22(5):30454. Available from: https://doi.org/10.2807/1560-9717.ES.2017.22.5.30454
10. Freidil GS, Sondier GJ, Bovêz LF, Friesema IH, van Rijckevorsel GG, Ruijs WL, et al. Hepatitis A outbreak among men who have sex with men (MSM) predominantly linked with the EuroPride, the Netherlands, July 2016 to February 2017. Euro Surveill [Internet]. 2017 [cited 2020 Oct 15];22(8):30468. Available from: https://doi.org/10.2807/1560-9717.ES.2017.22.8.30468
11. Chen GJ, Lin KY, Sun HY, Sheng WH, Hsieh SM, Huang YC, et al. Incidence of acute hepatitis A among HIV-positive patients during an outbreak among MSM in Taiwan: impact of HAV vaccination. Liver Int [Internet]. 2018 Apr [cited 2020 Oct 15];38(4):594-601. Available from: https://doi.org/10.1111/liv.13468
12. Ministério da Saúde (BR). Secretaria de Vigilância em Saúde. Departamento de Doenças de Condições Crônicas e Infeccões Sexualmente Transmissíveis. Protocolo clínico e diretrizes terapêuticas para atenção integral às pessoas com infeccões sexualmente transmissíveis [Internet]. Brasília: Ministério da Saúde; 2020 [cited 2020 Oct 15]. Available from: http://www.aids.gov.br/pt-br/pub/2015/protocolo-clinico-e-diretrizes-terapeuticas-para-atencao-integral-pessoas-com-infeecoes
13. Kramvis, A. Genotypes and genetic variability of hepatitis B virus. Intervirology [Internet]. 2014 [cited 2020 Oct 15];57:141-50. Available from: https://doi.org/10.1159/000360947
14. Aguilera A, Trastoy R, Rodriguez-Frias F, Muñoz-Bellido JL, Melón S, Suárez A, Orduña A, et al. GEHEP 010 study: prevalence and distribution of hepatitis B virus genotypes in Spain (2000-2016). J Infect [Internet]. 2020 [cited 2020 Oct 15];81(4):600-6. Available from: https://doi.org/10.1016/j.jinf.2020.07.019
15. Inoue T, Tanaka Y. Hepatitis B virus and its sexually transmitted infection – an update. Microb Cell [Internet]. 2016 Sep [cited 2020 Oct 15];3(9):420-37. Available from: https://doi.org/10.1128/CMR.00046-19
16. World Health Organization - WHO. Guidelines for the prevention, care and treatment of persons with chronic hepatitis C infection [Internet]. Geneva: World Health Organization; 2015 [cited 2020 Oct 15]. Available from: https://www.who.int/hiv/pub/hepatitis/hepatitis-b-guidelines/en/
17. Souto FJD. Distribution of hepatitis B infection in Brazil: the epidemiological situation at the beginning of the 21st century. Rev Soc Bras Med Trop [Internet]. 2016 [cited 2020 Oct 15];49(1):11-23. Available from: https://doi.org/10.1590/0037-8682-0176-2015
18. Nguyen MH, Wong G, Gane E, Kao JH, Dusheiko G. Hepatitis B virus: advances in prevention, diagnosis, and therapy. Clin Microbiol Rev [Internet]. 2020 Feb [cited 2020 Oct 15];33(2):e00046-19. Available from: https://doi.org/10.1128/CMR.00046-19
19. Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource. Hepatology [Internet]. 2014 Jan [cited 2020 Oct 15];59(1):318-27. Available from: https://doi.org/10.1002/hep.27644
in infancy: a meta-analysis. Pediatr Infect Dis J [Internet]. 2013 [cited 2020 Oct 15];32(4):307-13. Available from: https://doi.org/10.1097/INF.0b013e318287db1b0

62. Yeo YH, Le MH, Chang ET, Henry L, Nguyen MH. Prevalence of undetectable vaccine-induced immunity against hepatitis B virus in US adults at high risk for infection. Hepatology [Internet]. 2019 Apr [cited 2020 Oct 15];69(4):1385-97. Available from: https://doi.org/10.1002/hep.32085

63. World Health Organization - WHO. Prevention of mother-to-child transmission of hepatitis B virus: guidelines on antiviral prophylaxis in pregnancy [Internet]. Geneva: World Health Organization; 2020 [cited 2020 Oct 15]. Available from: https://apps.who.int/iris/bitstream/handle/10665/33391/978924002078-0-eng.pdf?sequence=1&isAllowed=y

64. Hajarizadeh B, Grebely J, Martinello M, Matthews GV, Lloyd AR, Dore GJ. Hepatitis C treatment as prevention: evidence, feasibility, and challenges. Lancet Gastro Hepatol [Internet]. 2016 [cited 2020 Oct 15];(4):317-27. Available from: https://doi.org/10.1016/S2468-1253(16)30075-9

65. Duarte G, Coutinho CM, Metzker RC. Hepatites B e C em gestantes. In: Madi JM, Araujo BF, Zatti H. Doenças infecciosas na prática obstétrica e neonatal. Rio de Janeiro: Editora Ruby; 2008. p. 49-57.

66. Seto MT, Cheung KW, Hung IFN. Management of viral hepatitis A, C, D and E in pregnancy. Best Pract Res Clin Obstet Gynaecol [Internet]. 2020 [cited 2020 Oct 15];1(4):371-8. Available from: http://dx.doi.org/10.1016/j.bpobgyn.2020.03.009

67. Duarte G. Extensão da assistência pré-natal ao parceiro como estratégia de aumento da adesão ao pré-natal e redução da transmissão vertical de infeccões. Rev Bras Ginecol Obstet [Internet]. 2007 Apr [cited 2020 Oct 15];29(4):171-4. Available from: http://dx.doi.org/10.1590/S0100-72302007000400001

68. Ranger-Rogez S, Alain S, Denis F. Virus des hépatites: transmission mère-enfant [Hepatitis viruses: mother to child transmission]. Pathol Biol (Paris) [Internet]. 2002 Nov [cited 2020 Oct 15];50(11):771-7. Available from: https://doi.org/10.1016/s0244-0938(02)00351-6

69. Rac MW, Sheffield JS. Prevention and management of viral hepatitis in pregnancy. Obstet Gynecol Clin North Am [Internet]. 2014 [cited 2020 Oct 15];41(4):573-92. Available from: https://doi.org/10.1016/j.ogc.2014.08.004

70. Nelson NP, Weng MK, Hofmeister MG, Moore KL, Doshani M, Kamili S, et al. Prevention of hepatitis A virus infection in the united states: recommendations of the advisory committee on immunization practices, 2020. MMWR Recomm Rep [Internet]. 2020 Jul [cited 2020 Oct 15];69(4):1385-97. Available from: https://doi.org/10.15585/mmwr.rr6905a1

71. Cheung KW, Lao TT. Hepatitis B – vertical transmission and the prevention of mother-to-child transmission. Best Pract Res Clin Obstet Gynaecol [Internet]. 2020 Mar [cited 2020 Oct 15];68:78-88. Available from: https://doi.org/10.1016/j.bpobgyn.2020.02.014

72. Indolfi G, Easterbrook P, Dusheiko G, Siberry G, Chang MH, Thorne C, et al. Hepatitis B virus infection in children and adolescents. Lancet Gastroenterol Hepatol [Internet]. 2019 Jun [cited 2020 Oct 15];4(6):466-76. Available from: https://doi.org/10.1016/S2468-1253(19)30042-1

73. United States Preventive Services Task Force, Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, et al. Screening for hepatitis B virus infection in pregnant women: US preventive services task force reaffirmation recommendation statement. JAMA [Internet]. 2019 Jul [cited 2020 Oct 15];322(4):349-54. Available from: https://doi.org/10.1001/jama.2019.9365

74. Ministério da Saúde (BR). Secretaria de Vigilância em Saúde. Departamento de Vigilância, Prevenção e Controle das Infeções
Sexualmente Transmissíveis, do HIV/ AIDS e das Hepatites Virais. Protocolo clínico e diretrizes terapêuticas para prevenção da transmissão vertical de HIV, sífilis e hepatites virais [Internet]. Brasília: Ministério da Saúde; 2019 [citado 2020 Oct 15]. Available from: http://www.aids.gov.br/pt-br/pub/2015/protocolo-clinico-e-diretrizes-terapeuticas-para-prevencao-da-transmissao-vertical-de-hiv

75. Schillie S, Vellozzi C, Reingold A, Harris A, Haber P, Ward JW, et al. Prevention of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep [Internet]. 2018 Jan [cited 2020 Oct 15];67(1):1-31. Available from: https://doi.org/10.15585/mmwr.r6701a1

76. Lobstein S, Faber R, Tillmann HL. Prevalence of hepatitis B among pregnant women and its impact on pregnancy and newborn complications at a tertiary hospital in the eastern part of Germany. Digestion [Internet]. 2011 [cited 2020 Oct 15];83(1-2):76-82. Available from: https://doi.org/10.1159/000320455

77. Pan CQ, Duan ZP, Bhamidimarri KR, Zou HB, Liang XF, Li J, et al. An algorithm for risk assessment and intervention of mother to child transmission of hepatitis B virus. Clin Gastroenterol Hepatol [Internet]. 2012 May [cited 2020 Oct 15];10(5):452-9. Available from: https://doi.org/10.1016/j.cgh.2011.10.041

78. Kwon SY, Lee CH. Epidemiology and prevention of hepatitis B virus infection. Korean J Hepatol [Internet]. 2011 Jun [cited 2020 Oct 15];17(2):87-95. Available from: https://doi.org/10.3350/kjhep.2011.17.2.87

79. Pan CQ, Duan Z, Dai E, Zhang S, Han G, Wang Y, et al. China study group for the mother-to-child transmission of hepatitis B. Tenofovir to prevent hepatitis B transmission in mothers with high viral load. N Engl J Med [Internet]. 2016 Jun [cited 2020 Oct 15];374(24):2324-34. Available from: https://doi.org/10.1056/NEJMoa1508660

80. Ayoub WS, Cohen E. Hepatitis B management in the pregnant patient: an update. J Clin Transl Hepatol [Internet]. 2016 Sep [cited 2020 Oct 15];4(3):241-7. Available from: https://doi.org/10.4121/jcth.2016.00014

81. National Institutes of Health (USA). Drugs and lactation database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine; 2020 [cited 2020 Oct 15]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK501744/

82. Society for Maternal-Fetal Medicine - SMFM, Dionne-Odom J, Tita AT, Silverman NS. #38: Hepatitis B in pregnancy screening, treatment, and prevention of vertical transmission. Am J Obstet Gynecol [Internet]. 2016 Jan [cited 2020 Oct 15];214(1):6-14. Available from: https://doi.org/10.1016/j.ajog.2015.09.100

83. Woodring J, Pastore R, Brink A, Ishikawa N, Takashima Y, Tohme RA. Progress toward hepatitis B control and elimination of mother-to-child transmission of hepatitis B virus – Western Pacific Region, 2005-2017. MMWR Morb Mortal Wkly Rep [Internet]. 2019 Mar [cited 2020 Oct 15];68(8):195-200. Available from: https://doi.org/10.15585/mmwr.mm6808a2

84. Zheng H, Zhang GM, Chan PL, Wang FZ, Rodewald LE, Miao N, et al. Compliance among infants exposed to hepatitis B virus in a post-vaccination serological testing program in four provinces in China. Infect Dis Poverty [Internet]. 2019 Jul [cited 2020 Oct 15];8(1):57. Available from: https://doi.org/10.1186/s40249-019-0568-y

85. Huang H, Xu C, Liu L, Chen L, Zhu X, Chen J, et al. Increased protection of earlier use of immunophrophylaxis in preventing perinatal transmission of hepatitis B virus. Clin Infect Dis [Internet]. 2020 Jul [cited 2020 Oct 15];ciaa898. Available from: https://doi.org/10.1093/cid/ciaa898

86. Castillo E, Murphy K, van Schalkwyk J. No. 342-hepatitis B and pregnancy. J Obstet Gynecol Can [Internet]. 2017 [cited 2020 Oct 15];39(3):181-90. Available from: https://doi.org/10.1016/j.jogc.2016.11.001

87. Ministério da Saúde (BR). Programa Nacional de Imunização. Anexo V: instrução normativa referente ao calendário nacional de vacinação 2020 [Internet]. Brasília: Ministério da Saúde; 2019 [citado 2020 Oct 15]. Available from: https://www.saude.gov.br/images/pdf/2020/marco/04/Instru-----Normativa-Calend--rio-Vacinal-2020.pdf

88. Brasil. Ministério da Saúde. Secretaria de Ciência, Tecnologia, Inovação e Insumos Estratégicos em Saúde. Departamento de Gestão e Incorporação de Tecnologias e Inovação em Saúde. Portaria MS/SCTIE Nº 32, de 11 de agosto de 2020. Torna pública a decisão de incorporar a testagem universal para hepatite viral C em gestantes no pré-natal, conforme protocolo do Ministério da Saúde, no âmbito do Sistema Único de Saúde – SUS [Internet]. Diário Oficial da União, Brasília (DF), 2020 Aug 19 [cited 2020 Oct 15];Seção 1:18. Available from: http://conitec.gov.br/images/Relatorios/Portaria/2018/Portaria_SCTIE_N42_05_10_2018.pdf

89. Jhaeveri R, Broder T, Bhattacharya D, Peters MG, Kim AY, Jonas MM. Universal screening of pregnant women for hepatitis C: the time is now. Clin Infect Dis [Internet]. 2018 [cited 2020 Oct 15];67(10):1493-7. Available from: https://doi.org/10.1093/cid/civ586

90. Rossi RM, Wolfe C, Brokamp R, McAllister JM, Wexelblatt S, Warshak CR, Hall ES. Reported prevalence of maternal hepatitis C virus infection in the United States. Obstet Gynecol [Internet]. 2020 Feb [cited 2020 Oct 15];135(2):387-95. Available from: https://doi.org/10.1097/AOG.0000000000003644

91. Conte D, Fraquelli M, Prati D, Colucci A, Minola E. Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women. Hepatology [Internet]. 2000 Mar [cited 2020 Oct 15];31(3):751-5. Available from: https://doi.org/10.1002/hep.51031028

92. Syriopoulou, V, Nikolopoulou G, Daikos GL, Theodoridou M, Pavlopoulou I, Nicolaidou P, et al. Mother to child transmission of hepatitis C virus: rate of infection and risk factors. Scand J Infect Dis [Internet]. 2005 [cited 2020 Oct 15];37(5):350-3. Available from: https://doi.org/10.1080/00365540510032105

93. Benova L, Mohamoud YA, Calvert C, Abu-Raddad LJ. Vertical transmission of hepatitis C virus: systematic review and meta-analysis. Clin Infect Dis [Internet]. 2014 Sep [cited 2020 Oct 15];59(6):765-73. Available from: https://doi.org/10.1093/cid/ciu447

94. Society for Maternal-Fetal Medicine - SMFM, Hughes BL, Page CM, Muller JA. Hepatitis C in pregnancy: screening, treatment, and management. Obstet Gynecol Sur [Internet]. 2017 Nov [cited 2020 Oct 15];217(5):B2-12. Available from: https://doi.org/10.1097/AJO.0000000000003590

95. Pappalardo BL. Influence of maternal human immunodeficiency virus (HIV) co-infection on vertical transmission of hepatitis C virus (HCV): a meta-analysis. Int J Epidemiol [Internet]. 2003 Oct [cited 2020 Oct 15];32(5):727-34. Available from: https://doi.org/10.1093/ije/dyg107

96. Hadzie N. Hepatitis C in pregnancy. Arch Dis Child Fetal Neonatal Ed [Internet]. 2001 May [cited 2020 Oct 15];84(3):F201-4. Available from: https://doi.org/10.1136%2Ffn.84.3.F201

97. Pappalardo BL. Influence of maternal human immunodeficiency virus (HIV) co-infection on vertical transmission of hepatitis C virus (HCV): a meta-analysis. Int J Epidemiol [Internet]. 2003 Oct [cited 2020 Oct 15];32(5):727-34. Available from: https://doi.org/10.1093/ije/dyg107

98. Page CM, Hughes BL, Rhee EHJ, Muller JA. Hepatitis C in pregnancy: review of current knowledge and updated recommendations for management. Obstet Gynecol Surv [Internet]. 2017 [cited 2020 Oct 15];72(6):347-55. Available from: https://doi.org/10.1097/OGX.0000000000000442

99. Rossi RM, Wolfe C, Brokamp R, McAllister JM, Wexelblatt S, Warshak CR, Hall ES. Reported prevalence of maternal hepatitis C virus
infection in the United States. Obstet Gynecol [Internet]. 2020 Feb [cited 2020 Oct 15];135(2):387-95. Available from: https://doi.org/10.1097/AOG.0000000000003644

99. Kushner T, Terrault NA. Hepatitis C in pregnancy: a unique opportunity to improve the hepatitis C cascade of care. Hepatol Commun [Internet]. 2018 Nov [cited 2020 Oct 15];3(1):20-8. Available from: https://doi.org/10.1002/hep4.1282

100. European Paediatric Hepatitis C Virus Network. Effects of mode of delivery and infant feeding on the risk of mother-to-child transmission of hepatitis C virus. BJOG [Internet]. 2001 Apr [cited 2020 Oct 15];108(4):371-7. Available from: https://doi.org/10.1111/j.1471-0528.2001.00088.x